Begalin-P (Ampicillin, Sulbactam)

Begalin-P is indicated for the treatment of several types of bacterial infections where ampicillin alone may be insufficient due to beta‑lactamase production.

• Respiratory tract infections, such as community‑acquired pneumonia and acute exacerbations of chronic bronchitis.
• Urinary tract infections, including complicated and uncomplicated cases.
• Intra‑abdominal infections, for example peritonitis, appendicitis, and intra‑operative prophylaxis.
• Skin and soft‑tissue infections, such as cellulitis, wound infections, and diabetic foot infections.
• Septicemia caused by susceptible organisms.

Adverse reactions reported with Begalin-P reflect the typical safety profile of ampicillin/sulbactam combinations.

Common

• Nausea or vomiting
• Diarrhea, which may be mild to moderate
• Skin rash or pruritus
• Pain, erythema, or swelling at the injection site
• Transient elevation of liver enzymes

Serious

• Severe hypersensitivity reactions, including anaphylaxis
• Clostridioides difficile‑associated colitis
• Neutropenia or agranulocytosis
• Thrombocytopenia
• Seizures, particularly in patients with renal impairment or high doses

Before prescribing Begalin-P, clinicians should evaluate patient history and laboratory data to mitigate potential risks.

• Known hypersensitivity to penicillins, sulbactam, or other beta‑lactam antibiotics.
• Renal impairment may require dosage adjustment and close monitoring.
• Caution in patients with a history of colitis or recent antibiotic‑associated diarrhea.
• Monitor liver function tests during prolonged therapy.
• Avoid use in neonates and infants younger than two months.
• Assess pregnancy and lactation status; data are limited.
• Use cautiously with other nephrotoxic or ototoxic agents.

Begalin-P can interact with other medicines, influencing efficacy or safety.

Avoid

• Allopurinol (increased risk of rash)
• Methotrexate (enhanced toxicity)
• Oral contraceptives (reduced effectiveness)

Use with caution

• Diuretics (potential electrolyte disturbances)
• Anticoagulants such as warfarin (possible INR alteration)
• Other nephrotoxic drugs, e.g., aminoglycosides
• Live vaccines (possible reduced immune response)